HLA-A allele mismatch (7/8 or 9/10) is the second best option after 8/8 or 10/10 matched unrelated donors: An analysis on results from Turkish centers

Basit Öğe Kaydı
dc.contributor.authorBeksaç, Meral
dc.contributor.authorSavran Oğuz, Fatma
dc.contributor.authorTopçuoğlu, Pervin
dc.contributor.authorKarasu, Gülsun
dc.contributor.authorArat, Mutlu
dc.contributor.authorAksoylar, Serap
dc.contributor.authorKansoy, Savaş
dc.contributor.authorKalayoğlu Beşışık, Sevgi
dc.contributor.authorKüpesiz, Alphan
dc.contributor.authorHazar, Volkan
dc.contributor.authorAltuntaş, Fevzi
dc.contributor.authorÜnal, Ali
dc.contributor.authorGülbaş, Zafer
dc.contributor.authorSargın, Fatma Deniz
dc.contributor.authorİlhan, Osman
dc.contributor.authorGürman, Günhan
dc.contributor.authorYeşilipek, Akif
dc.date.accessioned2020-06-29T14:05:49Z
dc.date.available2020-06-29T14:05:49Z
dc.date.issued2015
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractIntroduction: Hematopoietic stem cell transplantation (HSCT) from an unrelated donor has been established as an effective treatment option for patients with hematological diseases who lack a human leukocyte antigen (HLA)-matched related donor. However, HLA mismatch at the genetic level (allele mismatch) may be observed among serologically HLAmatched (antigen match) donor-recipient pairs, which adversely affects the incidence of severe graft-versus-host disease (GVHD) and survival. The aim of this retrospective multicenter study was to evaluate the impact of HLA mismatch on unrelated transplantation outcomes in Turkey. Materials (or patients) and methods: The data set consisted of follow-up records of 444 (of which 436 with HLA matching data available) unrelated-donor stem cell transplantations performed at 14 centers between July 2002- September 2014 and facilitated by TRAN orTRIS .215 patients underwent single antigen and/or allele-mismatched (mm) HSCT. The distribution of the mismatches according to the HLA-A, HLA-B, HLA-C, and HLA-DR and HLA-DQ loci are:82, 58, 32, 35 and 9 patients, respectively.Twelve patients were transplanted with 8/10 HLA matching. The patients’ characteristics are summarized in Table 1. Results: The neutrophil engraftment was achieved in 82.2% of the patients. HLA mm has a negative impact on engraftment (HLA mm: median 17days vs HLA-matched: median 16 days, p=0.03). Acute GVHD wasobserved at a rate of 42.1%. HLA matching did not have an impact on the incidence of acute GvHD (p=0.35) but chronic GvHD was more frequent among HLA allele /antigen mismatched patients than HLA-matched (p=0.008). The possibility of 5-year overall survival (OS) was 50.2%±2.5%. The presence of HLA mismatch significantly shortened the OS (58.9±3.4% vs Allele mm: 49.8±5.7% vs Antigen mm 36.0±4.9%, p<0.0001).Among the allele level mm HLA-A mm was associated with better OS compared to other loci (55.9±11.7%vs. 17.2±8.2%). When analysis was performed regardless of HLA match or only among HLA matched donor-recipient-pairsgender and stem cell source (PB vs BM) did not have an impact on OS. The OS of patients transplanted between 2002-2007 were shorter than those transplanted later (2008-2014)(37.9±6.4% vs. 52.9±2.7; p= 0.02).
dc.description.sponsorshipEuropean Society for Blood and Marrow Transplantationen_US
dc.identifier.citationBeksaç, M., Savran Oğuz, F., Topçuoğlu, P., Karasu, G., Arat, M., Aksoylar, S. ... Yeşilipek, A. (2015). HLA-A allele mismatch (7/8 or 9/10) is the second best option after 8/8 or 10/10 matched unrelated donors: An analysis on results from Turkish centers. 41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation içinde (S361-S362. ss.). Istanbul, Turkey, March 22-25, 2015.
dc.identifier.endpageS362
dc.identifier.issn0268-3369
dc.identifier.issn1476-5365
dc.identifier.issueSupplement: 1
dc.identifier.startpageS361
dc.identifier.urihttps://hdl.handle.net/20.500.12511/5335
dc.identifier.volume50
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherNature Publishing Group
dc.relation.ispartof41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantationen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHLA Mismatch
dc.subjectSurvival
dc.subjectUnrelated Donor
dc.titleHLA-A allele mismatch (7/8 or 9/10) is the second best option after 8/8 or 10/10 matched unrelated donors: An analysis on results from Turkish centers
dc.typeConference Object

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
sargin, fatma-2015.pdf
Boyut:
145.59 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Bildiri Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu